Gapping up
In reaction to earnings/guidance:
- CDNA +16.2%, QLYS +11.3%, HIMX +10.7%, AVID +10.4%, ARLO +9.7%, SBH +8.6%, BCRX +8.5%, GIL +8.1%, RUN +6.5%, RLJ +6.1%, CDAY +6.1%, ZNGA +5.6% (also to acquire Chartboost), AOSL +5.3%, HEAR +5.1%, OSUR +5.1%, QTWO +5%, BUD +5%, PRIM +4.6%, PYPL +4.6%, PZZA +4.2%, NUS +4%, SIMO +3.9%, ROOT +3.7%, APA +3.7%, TNDM +3.6%, DGII +3.5%, CCRN +3.5%, FVRR +3.3%, VSTO +3.3%, CSGS +3.1%, TMX +3.1%, TEN +3.1%, HUBS +3%, CARS +3%, BLDR +2.9%, VIAC +2.9%, BKI +2.9%, PDCE +2.8%, VNT +2.8%, NVST +2.7%, FRT +2.6%, BLD +2.6%, BAND +2.5%, IRM +2.5%, MELI +2.2%, RCII +2.2%, AES +2.2%, XXII +2.2%, PING +2.1%, STAA +2.1%, WCC +2.1%, ADNT +2.1%, COMM +2%, HL +1.9%, EPAM +1.9%, NRG +1.9%, WBT +1.7%, ICPT +1.7%, NBIX +1.5%, RSG +1.5%, AG +1.5%, ECOM +1.4%, QRVO +1.3%, UGI +1.3% (also increases dividend), MT +1.3%, RGR +1.2%, SKT +1.2%, PRLB +1.2%, MDU +1.1%, MGA +1.1%, PQG +1.1%, STOR +1.1%, VG +1.1%, MMS +1%
Other news:
- LKCO +24.3% (announces favorable court ruling granting preliminary injunction)
- HOME +16.5% (in talks with Hellman & Friedman for take-private deal, according to WSJ)
- ORGS +11.2% (has been granted Investigational Device Exemption approval by the United States Food and Drug Administration to conduct a first-in-human feasibility study of the Tissue Genesis Icellator2 to treat Acute Respiratory Distress Syndrome resulting from COVID-19 infection)
- TRVN +9.6% (announces selection of TRV027 for NIH-funded ACTIV initiative for COVID-19 trial)
- MNOV +4.5% (receives Notice of Intention to Grant from the European Patent Office for a pending patent application which covers the combination of MN-166 (ibudilast) and riluzole for the treatment of amyotrophic lateral sclerosis)
- AGTC +4.4% (reports "positive" 12-month data from highest dose groups in its ongoing XLRP Phase 1/2 clinical trial)
- CWH +4% (to acquire Hilmerson RV)
- CEQP +3.8% (files for 6 mln common unit offering by selling shareholders)
- KLR +3.8% (to build communication solutions with Trellance for credit unions)
- ASO +2.8% (prices offering of 14 mln shares of common stock at $32.00 per share)
- ADCT +2.2% (ZYNLONTA has been included in the latest National Comprehensive Cancer Network Clinical Practice Guidelines in oncology for B-cell Lymphomas) AG +1.5% (files for US$300 mln mixed securities shelf offering)
- LGIH +1.4% (reports April 2021 home closings)
- APEN +1.3% (files for $150 mln mixed securities shelf offering)
Analyst comments:
- PSNL +7.5% (upgraded to Outperform from Perform at Oppenheimer)
- RARE +5.8% (upgraded to Buy from Neutral at Citigroup)
- CMLS +4.9% (upgraded to Buy from Neutral at B. Riley Securities)
- EOLS +3.6% (upgraded to Buy from Neutral at Mizuho)
- WOW +3.3% (upgraded to Overweight from Equal-Weight at Stephens)
- FRT +2.6% (upgraded to Overweight from Neutral at Piper Sandler)
- MRCY +1.9% (upgraded to Buy from Hold at Jefferies)
- DRI +1.3% (upgraded to Outperform from Market Perform at Cowen)
- FLEX +1.3% (upgraded to Buy from Hold at Cross Research)
- NGG +1.1% (upgraded to Buy from Hold at Berenberg)
- ASTE +1% (upgraded to Buy from Hold at Stifel)